Bdellovibrio bacteriovorus therapy, an emerging alternative to antibiotics

IF 1.2 4区医学 Q4 CHEMISTRY, MEDICINAL

Letters in Drug Design & Discovery Pub Date : 2023-09-12 DOI:10.2174/1570180820666230912161923

Ibukun John Abulude, Daniel E Kadouri, Xianwu Guo

{"title":"Bdellovibrio bacteriovorus therapy, an emerging alternative to antibiotics","authors":"Ibukun John Abulude, Daniel E Kadouri, Xianwu Guo","doi":"10.2174/1570180820666230912161923","DOIUrl":null,"url":null,"abstract":"Abstract: The increase in multi-drug resistant (MDR) pathogens and the decline in the number of new antibiotics in the production pipeline pose a serious threat to our ability to treat infectious diseases. In this new landscape, once treatable diseases are now potentially life-threatening. This impending danger requires that urgent attention should be given to developing alternative strategies for combating MDR bacteria. A novel alternative is the use of predatory bacteria, B. bacteriovorus spp, that naturally prey on Gram-negative bacteria, including MDR Enterobacteriaceae. B. bacteriovorus has been shown to be non-pathogenic in animal models and on human cell lines, supporting its feasibility to be used to treat infections in animals and possibly humans. This document reviews various aspects of B. bacteriovorus biology, including its unique life cycle, \"predatory toolbox\", prey range, and recent research advances exploring B. bacteriovorus as an antimicrobial agent, stepping towards its use in human therapy. We also discuss the advantages and limitations of using B. bacteriovorus therapy and the strategies to overcome these limitations.","PeriodicalId":18059,"journal":{"name":"Letters in Drug Design & Discovery","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2023-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Letters in Drug Design & Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1570180820666230912161923","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Abstract: The increase in multi-drug resistant (MDR) pathogens and the decline in the number of new antibiotics in the production pipeline pose a serious threat to our ability to treat infectious diseases. In this new landscape, once treatable diseases are now potentially life-threatening. This impending danger requires that urgent attention should be given to developing alternative strategies for combating MDR bacteria. A novel alternative is the use of predatory bacteria, B. bacteriovorus spp, that naturally prey on Gram-negative bacteria, including MDR Enterobacteriaceae. B. bacteriovorus has been shown to be non-pathogenic in animal models and on human cell lines, supporting its feasibility to be used to treat infections in animals and possibly humans. This document reviews various aspects of B. bacteriovorus biology, including its unique life cycle, "predatory toolbox", prey range, and recent research advances exploring B. bacteriovorus as an antimicrobial agent, stepping towards its use in human therapy. We also discuss the advantages and limitations of using B. bacteriovorus therapy and the strategies to overcome these limitations.

查看原文本刊更多论文

Bdellovibrio bacterovous疗法，一种新兴的抗生素替代品

摘要:多药耐药(MDR)病原体的增加和新抗生素的生产数量的减少对我们治疗传染病的能力构成了严重威胁。在这种新的情况下，曾经可以治疗的疾病现在可能危及生命。这种迫在眉睫的危险要求我们紧急注意制定对抗耐多药细菌的替代战略。一种新的替代方法是使用掠食性细菌，即B. bacteriovorus spp，它自然捕食革兰氏阴性细菌，包括耐多药肠杆菌科。在动物模型和人类细胞系中，已证明B. bacteriovorus是非致病性的，这支持了将其用于治疗动物和可能的人类感染的可行性。本文综述了有关B. bacteriovorus生物学的各个方面，包括其独特的生命周期、“掠食性工具箱”、猎物范围，以及探索B. bacteriovorus作为抗微生物剂的最新研究进展，朝着其在人类治疗中的应用迈进。我们还讨论了使用芽孢杆菌治疗的优点和局限性以及克服这些局限性的策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Letters in Drug Design & Discovery 医学-医药化学

CiteScore

1.80

自引率

10.00%

发文量

245

审稿时长

3 months

期刊介绍： Aims & Scope Letters in Drug Design & Discovery publishes letters, mini-reviews, highlights and guest edited thematic issues in all areas of rational drug design and discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. The emphasis is on publishing quality papers very rapidly by taking full advantage of latest Internet technology for both submission and review of manuscripts. The online journal is an essential reading to all pharmaceutical scientists involved in research in drug design and discovery.